Brokerages predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will post ($0.57) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.77). Voyager Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which would indicate a positive year over year growth rate of 12.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Voyager Therapeutics will report full-year earnings of ($2.54) per share for the current financial year, with EPS estimates ranging from ($3.36) to ($1.20). For the next year, analysts forecast that the company will post earnings of ($3.28) per share, with EPS estimates ranging from ($4.70) to ($2.61). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, March 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative net margin of 697.03% and a negative return on equity of 63.18%. The company had revenue of $6.35 million during the quarter, compared to analysts’ expectations of $5.81 million.
NASDAQ:VYGR opened at $18.79 on Friday. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $31.91. The stock has a market capitalization of $605.17, a P/E ratio of -7.12 and a beta of 2.37.
In other news, insider Bernard Ravina sold 3,630 shares of Voyager Therapeutics stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $16.40, for a total transaction of $59,532.00. Following the transaction, the insider now directly owns 7,353 shares of the company’s stock, valued at $120,589.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Jane Henderson sold 17,316 shares of Voyager Therapeutics stock in a transaction on Monday, March 19th. The stock was sold at an average price of $22.11, for a total transaction of $382,856.76. Following the transaction, the chief financial officer now directly owns 15,416 shares in the company, valued at $340,847.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,087 shares of company stock worth $1,588,741. Insiders own 8.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in Voyager Therapeutics by 312.8% in the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after acquiring an additional 285,806 shares in the last quarter. Aevitas Wealth Management Inc. bought a new stake in Voyager Therapeutics in the 4th quarter valued at $1,400,000. Vanguard Group Inc. lifted its position in Voyager Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after acquiring an additional 13,194 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Voyager Therapeutics by 16.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock valued at $1,274,000 after acquiring an additional 8,633 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Voyager Therapeutics in the 4th quarter valued at $1,210,000. 78.22% of the stock is currently owned by institutional investors and hedge funds.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.